In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

Novo Nordisk's GLP-1 drugs like Ozempic and Wegovy are smash hits. However, another biotech is working on a few programs that could be far better. It has plenty of money, good preliminary results ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...